Mobia Medical, Inc. (MOBI) Stock Analysis 2026

HealthcareMedical Devices

MOBI Revenue & Profitability Breakdown

This chart shows how MOBI's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$45.3M
Cost of Revenue
-$8.3M
Gross Profit
$37.0M81.7% margin
Operating Expenses
-$37.0M
Operating Income
$0-132.7% margin
Tax & Other
-$64.1M
Net Income
-$-64.1M-141.6% margin
Gross Margin
81.7%
Operating Margin
-132.7%
Net Margin
-141.6%

Key Financial Metrics

Mobia Medical, Inc. doesn't carry a meaningful trailing P/E right now, hasn't disclosed meaningful free cash flow, runs a debt/equity ratio of 4.88, and hasn't disclosed return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$346.6M
P/E (Forward)
-4.72
Price / Book
2.01
Revenue
$45.3M
Revenue Growth
102.4%
EPS (Trailing)
$-2.96
EPS (Forward)
$-2.20
Gross Margin
81.7%
Operating Margin
-132.7%
Net Margin
-141.6%
Debt / Equity
4.88
Current Ratio
13.28
Quick Ratio
12.63
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
19.6%
Inst. Ownership
63.1%
Short % Float
1.8%
Book Value / Share
$5.19

Wall Street Analyst Consensus

Wall Street analysts covering Mobia Medical, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $17.75. Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$17.75

Technical Price Signals

MOBI is currently in a mixed technical position. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

50-Day MA
$10.05
200-Day MA
$11.45

Further Reading

Research and guides that put MOBI’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

Market TheoryStock Market Seasonality: Monthly Returns, 'Sell in May,' and What History SaysMarket TheoryWe Backtested 929 Insider Cluster Buys — The Signal Everyone Trusts Loses to the S&P 500Fundamentals58% of Insider Selling Is Noise — How to Find the Part That MattersMarket TheoryThe Stock-Split Pop Is a Myth: What 39 Real Splits Actually Did

More Healthcare Stock Analysis

In-depth reports on companies operating alongside MOBI — business models, bull and bear cases, and the metrics that matter.

ZBHZimmer Biomet Holdings, Inc.Medical DevicesSYKStryker CorporationMedical DevicesSTESTERIS plcMedical DevicesMDTMedtronic plcMedical DevicesGEHCGE HealthCare Technologies Inc.Medical DevicesDXCMDexCom, Inc.Medical DevicesEWEdwards Lifesciences CorporationMedical DevicesBSXBoston Scientific CorporationMedical Devices

Unlock the Full MOBI Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis